Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of ligustilide in preparing composition for preventing and treating senile dementia

A technology of ligustilide and senile dementia, which is applied in the field of application of ligustilide in the preparation of compositions for preventing and treating senile dementia, and can solve the problems of affecting the clinical prevention and treatment effect of senile dementia, poor long-term treatment effect, large adverse reactions, etc. question

Inactive Publication Date: 2010-12-08
SICHUAN UNIV
View PDF8 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, a large number of studies have found that most of the existing drugs have poor long-term treatment effects, large adverse reactions, difficulty in penetrating the blood-brain barrier, difficulty in absorption, or lack of specific and integrated intervention effects on the complex pathogenesis of senile dementia. Seriously affect the clinical prevention and treatment effect of these drugs on senile dementia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ligustilide in preparing composition for preventing and treating senile dementia
  • Application of ligustilide in preparing composition for preventing and treating senile dementia
  • Application of ligustilide in preparing composition for preventing and treating senile dementia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Ligustilide (LIG) protects SH-SY5Y cell injury induced by Aβ amyloid peptide

[0035] Cell culture: human neuroblastoma cells SH-SY5Y cell line was purchased from ATCC, USA. SH-SY5Y cells use high-glucose DMEM complete medium [containing 10% (V / V) FBS, 1% (V / V) NEAA, 100U / ml penicillin, 100μg / ml streptomycin], at 37°C, 5% CO 2 , cultured in a cell incubator with saturated humidity. The culture medium was changed every 2-3 days and subcultured every 4-6 days. Cells in the logarithmic growth phase were inoculated on culture plates for different experiments.

[0036] Reagents and medicines:

[0037] N-2supplement American Gibco company

[0038] Non-Essential Amino Acids (NEAA) Sigma Corporation of America

[0039] Aβ(25-35) Sigma, USA

[0040] TNF-α polyclonal antibody American CST company

[0041] Cox2 polyclonal antibody US CST company

[0042] The rest of the reagents were commercially available analytically pure.

[0043] instrument:

[0044] ESCO Class II B...

Embodiment 2

[0069] Effects of Ligustilide on Memory Impairment in Rats Induced by Brain Stereotaxic Injection of Aβ Amyloid Peptide

[0070] Animals: male Wistar rats, weighing 300-350 g, SPF grade, purchased from the Institute of Experimental Animals, Academy of Sciences, Sichuan Medical Academy. After the room temperature was kept at about 25°C, they were free to eat and drink.

[0071] Reagents and medicines: the chemical purity of ligustilide used is >98%, prepared with 3% Tween-80;

[0072] The rest of the reagents were commercially available analytically pure.

[0073] Instruments: Morris water maze, recorder, etc.

[0074] Preparation of Aβ(25-35) solution:

[0075] Aβ(25-35) solution (5mM / l) was prepared with sterile physiological saline, aged at 37°C for 7 days according to the literature method, and then used for later use.

[0076] Model establishment of memory dysfunction in rats induced by stereotaxic injection of Aβ amyloid peptide:

[0077] After the experimental rats ...

Embodiment 3

[0086] Effects of ligustilide on neuronal injury in rats induced by stereotaxic injection of Aβ amyloid peptide

[0087] Animals: male Wistar rats, weighing 300-350 g, SPF grade, purchased from the Institute of Experimental Animals, Sichuan Academy of Medical Sciences. After the room temperature was kept at about 25°C, they were free to eat and drink.

[0088] Reagents and medicines: the chemical purity of ligustilide used is >98%, prepared with 3% Tween-80;

[0089] The rest of the reagents were commercially available analytically pure.

[0090] Preparation of Aβ(25-35) solution

[0091] Prepare Aβ(25-35) solution (5mM / l) with sterile normal saline, and aging it at 37°C for 7 days according to the method in the literature.

[0092] Establishment of a model of memory dysfunction in rats induced by stereotaxic injection of Aβ amyloid peptide

[0093] After the experimental rats were anesthetized with 1% sodium pentobarbital (40 mg / kg), the head was fixed with a stereotaxic ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an application of ligustilide in preparing a composition for preventing and treating senile dementia, which comprises ligustilide as an effective component and other components acceptable pharmaceutically and / or acceptable in food or auxiliary components. As required, the effective components can comprise at least one of acetylcholinesterase inhibitor, excitatory amino acid and peptide transmitter components, Abeta fibration and sedimentation disturbance components, antioxidant, microcirculation improving components and calcium antagonist accounting for 10%-40% of the total weight. Shown by experimental results, through the protective actions of the ligustilide on damage caused by oxidation, apoptosis and inflammatory reaction induced by the Abeta amyloid peptide fragment and aging neuron degenerative change, the composition can obviously improve the descending of learning and memory caused by the Abeta amyloid peptide fragment and the aging neuron degenerative change, and can be used as a medicine and / or a health food composition.

Description

technical field [0001] The invention relates to a new medical application of ligustilide, in particular to the application in preparing compositions for preventing and treating senile dementia, including medicines and / or health-care edible compositions. Background technique [0002] Senile dementia is a common and frequently-occurring disease that seriously threatens the health of the elderly. Patients experience persistent and comprehensive mental decline in a conscious state, manifested in memory, comprehension, calculation, judgment, orientation, language, abstract thinking, and self-control. Impairment of other abilities, leading to the loss of independent living and working ability of patients. Senile dementia is a group of syndromes of high-level brain dysfunction caused by chronic progressive brain structure and organic damage, and its etiology has not yet been fully elucidated. Studies have shown that amyloid beta peptide (Aβ) deposits amyloid deposits in areas rela...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/365A61P25/28A23L1/30A23L33/115
Inventor 杜俊蓉汪程远旷喜余彦陈娅姝王竞张梦雪
Owner SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com